The Leerink downgrade is a contrarian call from a low-accuracy firm, but the convergence with insider selling and elevated short interest creates a cautionary setup. Traders should monitor the August 5 earnings report for confirmation; a miss could accelerate the downside implied by the $127 target.
GILD drugs
GILD drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 21 $130.28entry
- T+1 · 4mo ago +0.05%α +0.16% · $130.34
- T+5 · 4mo ago +0.18%α +1.41% · $130.52
- T+20 · 3mo ago +10.10%α +7.54% · $143.44
- T+60 · 5w ago +13.54%α +9.57% · $147.92
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Leerink Partners double-downgraded Gilead Sciences from Outperform to Market Perform on July 21, slashing its price target to $127 from $146, implying 4.7% downside from the current $133.21. The downgrade is a contrarian call against a heavily bullish consensus, 81% of analysts rate GILD Buy/Strong Buy, with a mean target of $158.30 (19% upside). Leerink's accuracy is below average at 49% on 257 calls, and its average return of 4.3% trails top-tier firms like RBC Capital (93% accuracy, 14.9% return). Recent insider selling by the CEO and other executives in July, totaling ~$3M, aligns with the bearish analyst action. However, institutional buying remains strong, with MASSACHUSETTS FINANCIAL SERVICES adding 48.7% to its position. EPS revisions for the current year (+1y) have been slightly positive over the past 30 days. The next earnings report is due August 5, adding a timing catalyst. Traders should view this downgrade as a cautionary signal from a low-accuracy firm, but the convergence with insider selling warrants attention.
Impact Score
Consensus & Targets
The consensus is heavily bullish: 10 Strong Buy, 20 Buy, 7 Hold, 0 Sell, 0 Strong Sell, 81% Buy/Strong Buy from 27 analysts. The downgrade is a contrarian move against the prevailing bullish consensus.
Mean target $158.30, median $160, high $180, low $120. Current price $133.21 implies 18.8% upside to the mean. Leerink's new $127 target is below the low end of consensus ($120) and 19.8% below the mean, making it one of the most bearish targets on the Street.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-07-21 | Leerink Partners | downgrade | Market Perform | $127.00 |
| 2026-07-08 | Morgan Stanley | maintain | Overweight | $166.00 |
| 2026-07-07 | RBC Capital | maintain | Sector Perform | $120.00 |
| 2026-07-07 | Truist Securities | maintain | Buy | $156.00 |
| 2026-07-06 | Cantor Fitzgerald | reiterate | Overweight | $155.00 |
| 2026-07-06 | HSBC | upgrade | Buy | $155.00 |
| 2026-06-16 | Cantor Fitzgerald | reiterate | Overweight | $155.00 |
| 2026-05-20 | Maxim Group | upgrade | Buy | $165.00 |
| 2026-05-08 | Truist Securities | reiterate | Buy | $157.00 |
| 2026-05-08 | RBC Capital | maintain | Sector Perform | $122.00 |
Over the past 30 days, analyst activity shows 1 upgrade (HSBC from Hold to Buy on July 6) and 1 downgrade (Leerink). EPS revisions for the current fiscal year (+1y) show 2 upward revisions vs 1 downward in the past 30 days, with the average estimate rising from $9.67 to $9.71. Near-term (+1q) estimates also saw 2 upward revisions with no downgrades.
Firm Track Record: Leerink Partners
Leerink Partners accuracy: 49% on 257 calls | avg return: 4.3%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| Truist Securities | 100% | 4/4 | 9.7% | top tier |
| TD Cowen | 100% | 2/2 | 16.2% | top tier |
| Citigroup | 100% | 2/2 | 8.3% | top tier |
| UBS | 100% | 3/3 | 11.5% | top tier |
| Mizuho | 100% | 2/2 | 16.8% | top tier |
| RBC Capital | 93% | 13/14 | 14.9% | top tier |
| Needham | 89% | 8/9 | 12.2% | top tier |
| BMO Capital | 86% | 6/7 | 7.6% | top tier |
| JP Morgan | 86% | 6/7 | 6% | top tier |
| Cantor Fitzgerald | 86% | 6/7 | 17.9% | top tier |
Leerink Partners has a 49% accuracy rate on 257 scored calls with an average return of 4.3%. This is below the top-tier firms covering GILD: RBC Capital (93% on 14 calls, 14.9% return), Cantor Fitzgerald (86% on 7 calls, 17.9% return), and Mizuho (100% on 2 calls, 16.8% return). Leerink's track record is among the weakest of firms covering GILD.
Earnings Estimates
Next earnings: Aug 5, 2026
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| 0q | $-7.30 | $-7.93 to $-6.40 | $7.4B | ↑1 ↓0 |
| +1q | $2.23 | $1.41 to $2.57 | $7.8B | ↑2 ↓0 |
| 0y | $-0.77 | $-1.05 to $-0.26 | $30.5B | ↑1 ↓0 |
| +1y | $9.71 | $9.05 to $11.20 | $32.4B | ↑1 ↓0 |
Cross-Platform Signals
Insider selling is notable: CEO O'Day sold ~$1.9M on July 1, and two other executives sold ~$780K on July 15, a bearish signal aligning with the downgrade. Congressional activity shows two small buys by Rep. Moskowitz (Democrat) in May. Institutional changes are mixed: MASSACHUSETTS FINANCIAL SERVICES added 48.7% ($910M position), while NORGES BANK exited completely. Short interest is elevated at 56.8% of off-exchange volume, indicating bearish positioning. The insider selling convergence with the downgrade adds weight to the bearish signal.
Investment Themes
Documents Analyzed
Report based on filing metadata.
Track record
30 reports on GILD
5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +22.38% at T+60 after the Aug 13, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $167.58 Now $167.58 +0.00% settles Feb 16
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $167.71 Now $167.58 −0.08% settles Feb 12
- Nov 13, 20264d ago Court Ruling Bullish 4/10 Entry $170.99 Now $167.58 −1.99% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $168.08 Now $167.58 −0.30% settles Feb 11
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $170.87 Now $167.58 −1.93% settles Feb 8
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $169.32 Now $167.58 −1.03% settles Feb 5
- Nov 4, 202612d ago 144 Neutral 3/10 Entry $167.57 Now $167.58 +0.01% settles Feb 3
- Oct 30, 202617d ago 144 Neutral 3/10 Entry $170.33 Now $167.58 −1.61% settles Jan 29
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $170.68 Now $167.58 −1.82% settles Jan 28
- Oct 22, 202625d ago Institutional Cluster Bearish 4/10 Entry $156.04 Now $167.58 −7.40% settles Jan 21
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers